Ascletis Becomes Another Contender For ‘Best-In-Class’ Oral GLP-1

 
• By Andrew McConaghie

ASC30's Phase I study has produced the best-yet weight loss achieved by an oral drug at 28 days, and it could be a serious rival for Lilly’s frontrunner orforglipron.

Jeans with a tape measure as a belt
Survodutide Achieved Up To 18.7% Weight Loss At 46 Weeks • Source: Shutterstock

More from Start-Ups & SMEs

More from Therapy Areas